Skip to content

Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker

Randomized Clinical Trial of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03830957
Enrollment
200
Registered
2019-02-05
Start date
2018-11-26
Completion date
2019-12-31
Last updated
2019-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CT Angiography, Heart Failure, Heart Failure,Congestive, Heart Failure, Diastolic, Heart Failure, Systolic, Heart Rate Low, Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy

Brief summary

The aim of this study is to compare the effects of Ivabradine and metoprolol to reduce heart rate prior to coronary CT angiography in patients with advanced heart failure.

Interventions

DRUGIvabradine

7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg

DRUGMetoprolol

5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg

Sponsors

Rajaie Cardiovascular Medical and Research Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Sinus rhythm * Heart rate \>60/min

Exclusion criteria

* Atrial fibrillation * Any contraindication for beta-blocker use

Design outcomes

Primary

MeasureTime frameDescription
Heart rate30 minutes before and after coronary CT angiographyChanging heart rate during imaging study

Secondary

MeasureTime frameDescription
Functional calss30 minutes before and after coronary CT angiography and 6 months laterHeart Failure severity has been classified according to New York Heart Association (NYHA) to: * Class I: No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF. * Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF. * Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF. * Class IV: Unable to perform any physical activity without symptoms of HF, or symptoms of HF at rest.
Blood pressure, systolic and diastolic30 minutes before and after coronary CT angiography and 6 months laterThe amount of blood pressure measured by sphygmomanometer
Sleep qualityBefore CT angiography and 6 months laterThe rate of disturbed sleep measured as better than before, Worse than before, and No change There are no standard classification for severity of this symptom. In our study, we measure this symptom as : * Better than before (1) * Worse than before (2) * No change (0)
Dyspnea30 minutes before and after coronary CT angiography and 6 months laterShortness of breath, or dyspnea, is the most famous symptom of left ventricular failure. It typically appears during strenuous activities, and progresses to ordinary activities, less than ordinary activities and ultimately resting state. The severity is categorized as above (FC 1 to 4)
Prolonged bradycardia30 minutes before and after coronary CT angiographyPersistence of Bradycardia more than 6 hours is called prolonged bradycardia.
Hypotension30 minutes before and after coronary CT angiographySystolic less than 80 mm Hg
AppetiteBefore CT angiography and 6 months laterThe rate of changing in appetite level measured as better than before, Worse than before, and No change Loss of appetite is a common symptom of heart failure. There are no standard classification for severity of this symptom. In our study, we measure this symptom as : * Better than before (1) * Worse than before (2) * No change (0)

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026